Google’s artificial intelligence arm DeepMind has been holding back the release of its world-renowned research, as it seeks ...

AI unit, has placed strict controls over the release of its research papers to maintain its competitive edge in ...

Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...

Demis Hassabis, a childhood chess prodigy, said his experience with the game afforded him his first brush with AI. He was ...

Gemini 2.5 Pro represents a significant step forward in AI model design, combining raw power with refined reasoning ...

Google DeepMind CEO Demis Hassabis's AI journey had an unexpected start: his early mastery of chess. Years before Hassabis ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

Alphabet’s Gemini 2.5 Pro sets new AI benchmarks, powered by DeepMind and custom TPUs. Learn why GOOG stock offers long-term ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

Gemini 2.5 Pro Experimental boosts accuracy by reasoning before responding, available in Google AI Studio and for Gemini ...

Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...